Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer’s disease patients and control subjects
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PurposeImaging of the 18-kDa translocator protein (TSPO) is a potential tool for examining microglial activation and neuroinflammation in early Alzheimer’s disease (AD). [18F]FEMPA is a novel high-affinity second-generation TSPO radioligand that has displayed suitable pharmacokinetic properties in preclinical studies. The aims of this study were to quantify the binding of [18F]FEMPA to TSPO in AD patients and controls and to investigate whether higher [18F]FEMPA binding in AD patients than in controls could be detected in vivo.MethodsTen AD patients (five men, five women; age 66.9 ± 7.3 years; MMSE score 25.5 ± 2.5) and seven controls (three men, four women; age 63.7 ± 7.2 years, MMSE score 29.3 ± 1.0) were studied using [18F]FEMPA at Turku (13 subjects) and at Karolinska Institutet (4 subjects). The in vitro binding affinity for TSPO was assessed using PBR28 in a competition assay with [3H]PK11195 in seven controls and eight AD patients. Cortical and subcortical regions of interest were examined. Quantification was performed using a two-tissue compartment model (2TCM) and Logan graphical analysis (GA). The outcome measure was the total distribution volume (VT). Repeated measures analysis of variance was used to assess the effect of group and TSPO binding status on VT.ResultsFive AD patients and four controls were high-affinity binders (HABs). Three AD patients and three controls were mixed-affinity binders. VT estimated with Logan GA was significantly correlated with VT estimated with the 2TCM in both controls (r = 0.97) and AD patients (r = 0.98) and was selected for the final analysis. Significantly higher VT was found in the medial temporal cortex in AD patients than in controls (p = 0.044) if the TSPO binding status was entered as a covariate. If only HABs were included, significantly higher VT was found in the medial and lateral temporal cortex, posterior cingulate, caudate, putamen, thalamus and cerebellum in AD patients than in controls (p < 0.05).Conclusion[18F]FEMPA seems to be a suitable radioligand for detecting increased TSPO binding in AD patients if their binding status is taken into account.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“[8].”
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“Post-mortem studies in AD patients have shown that microglial activation is associated with the presence of amyloid plaques [1], suggesting a link between amyloid pathology and neuroinflammation.”
BackgroundRupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930 · cited 1×
“The 18-kDa translocator protein (TSPO) is a mitochondrial protein [2, 3] expressed in macrophages [4], microglia [5] and reactive astrocytes [6], and is considered a marker of activated microglia and macrophages [7].”
BackgroundOwen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
Self-citationEdison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 2×
“This finding is in agreement with previous reports using either [(11)C](R)-PK11195 in AD patients (approximately 20 – 35% increased in cortical binding as compared with controls) [9], [(11)C]DAA1106 in MCI (26 % increase) and AD patients (18 % increase) [13, 14], or [(11)C]PBR28 in AD patients (38 % increase) [19].”
ResultCosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459 · cited 1×
“The 18-kDa translocator protein (TSPO) is a mitochondrial protein [2, 3] expressed in macrophages [4], microglia [5] and reactive astrocytes [6], and is considered a marker of activated microglia and macrophages [7].”
BackgroundIn vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350 · cited 3×
“This finding is in agreement with previous reports using either [(11)C](R)-PK11195 in AD patients (approximately 20 – 35% increased in cortical binding as compared with controls) [9], [(11)C]DAA1106 in MCI (26 % increase) and AD patients (18 % increase) [13, 14], or [(11)C]PBR28 in AD patients (38 % increase) [19].”
BackgroundResultKuhlmann, A. C., & Guilarte, T. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741694.x · Cited by 215
Yasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148 · cited 2×
“This finding is in agreement with previous reports using either [(11)C](R)-PK11195 in AD patients (approximately 20 – 35% increased in cortical binding as compared with controls) [9], [(11)C]DAA1106 in MCI (26 % increase) and AD patients (18 % increase) [13, 14], or [(11)C]PBR28 in AD patients (38 % increase) [19].”
BackgroundResult
Cited by
Hamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519
Werry, E. L., Bright, F. M., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kril, J. J., & Kassiou, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133161 · Cited by 279
Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis
Bradburn, S., Murgatroyd, C., & Ray, N. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.002 · Cited by 268
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
Chandra, A., Valkimadi, P., Pagano, G., Cousins, O., Dervenoulas, G., Politis, M., & Initiative, F. T. A. D. N. (2019) · Human Brain Mapping · doi:10.1002/hbm.24782 · Cited by 183
Microglial activation in Parkinson’s disease using [18F]-FEPPA
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0778-1 · Cited by 113
“However, previous investigations using second-generation TSPO radioligands have also presented a stronger disease effect on TSPO expression in AD patients [37].”
Sifting through the surfeit of neuroinflammation tracers
Cumming, P., Burgher, B., Patkar, O., Breakspear, M., Vasdev, N., Thomas, P., Liu, G.-J., & Banati, R. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17748786 · Cited by 111
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“Imaging Research Findings and Clinical Relevance In vivo TSPO imaging is generally able to discriminate between AD dementia patients and normal control subjects (Cagnin et al., 2001; Yasuno et al., 2008; Suridjan et al., 2015; Varrone et al., 2015; Hamelin et al., 2016; Kreisl et al., 2016a).”
BackgroundImaging Striatal Microglial Activation in Patients with Parkinson’s Disease
Koshimori, Y., Ko, J.-H., Mizrahi, R., Rusjan, P., Mabrouk, R., Jacobs, M. F., Christopher, L., Hamani, C., Lang, A. E., Wilson, A. A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138721 · Cited by 100
Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
“In terms of treatment for cognitive impairment, most studies have included patients treated for cognitive deficits (Yasuno et al., 2008; Wiley et al., 2009; Kreisl et al., 2013b; Varrone et al., 2013; Suridjan et al., 2015; Varrone et al., 2015; Hamelin et al., 2016).”
Mirzaei, N., Tang, S. P., Ashworth, S., Coello, C., Plisson, C., Passchier, J., Selvaraj, V., Tyacke, R. J., Nutt, D. J., & Sastre, M. (2016) · Glia · doi:10.1002/glia.22978 · Cited by 82
In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Garibotto, V., & Millet, P. (2020) · Cells · doi:10.3390/cells9091941 · Cited by 79
“VT VT Logan VT Logan HAB/MAB-AD > HAB/MAB-HC: medT HAB-AD > HAB-HC: medT, latT, pCin, Cau, Pu, Th, CE (+19%) No correlations between FEMPA and MMSE scores [73]”
BackgroundMethodResultInfluentialCerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75
“These new generation tracers include both carbon-11 and fluorine-18 radioligands, such as 11C-DPA713 [47], 11C-DAA1106 [48], 11C-PBR28 [49–51], 11C-vinpocetine [52], 18F-DPA714 [53], 18F-FEPPA [54], 18F-FEMPA [55] and 18F-FEDAA1106 [56–60], which have all been tested in a few human studies.”
BackgroundAstrocytic TSPO upregulation appears before microglial TSPO in Alzheimer’s disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Fraser, B. H., Grégoire, M.-C., Kövari, E., & Millet, P. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200136 · Cited by 65
Tournier, B. B., Tsartsalis, S., Rigaud, D., Fossey, C., Cailly, T., Fabis, F., Pham, T., Grégoire, M.-C., Kövari, E., Moulin-Sallanon, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.022 · Cited by 62
Metadata
- Authors
- Varrone, A., Oikonen, V., Forsberg, A., Joutsa, J., Takano, A., Solin, O., Haaparanta-Solin, M., Nag, S., Nakao, R., Al-Tawil, N., Wells, L. A., Rabiner, E. A., Valencia, R., Schultze-Mosgau, M., Thiele, A., Vollmer, S., Dyrks, T., Lehmann, L., Heinrich, T., Hoffmann, A., Nordberg, A., Halldin, C., & Rinne, J. O.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2014-11-21
- Volume
- 42
- Issue
- 3
- Pages
- 438-446
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2170978964
- Cited by
- 79
- References
- 9
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.